Anti-CD3-anti-HER2/neu-activated T cells - TransTarget

Drug Profile

Anti-CD3-anti-HER2/neu-activated T cells - TransTarget

Alternative Names: Anti-CD3 activated T cells targeted with anti-CD3-anti-HER2 bispecific antibody; ATC targeted with HER2Bi; HER2Bi-armed ATC

Latest Information Update: 05 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TransTarget
  • Developer Barbara Ann Karmanos Cancer Institute; National Cancer Institute (USA)
  • Class Bispecific antibodies; Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action Apoptosis stimulants; CD3 antigen inhibitors; ERBB 2 receptor antagonists; Immunostimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 18 Dec 2009 Phase-II clinical trials in Breast cancer in USA (IV)
  • 03 Jun 2008 Phase-I clinical trials in Breast cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top